Patented and Proprietary, the Company's Immune Booster is One of
Very Few Hemp-Enhanced, FDA Registered Products with a Claim for
Boosting the Immune System's Effectiveness Against Invading
Pathogens
South
Easton, MA, May 28, 2020 – InvestorsHub
NewsWire -- Pressure BioSciences, Inc. -- (OTCQB: PBIO) ("PBI" or the "Company"), a leader
in the development and sale of broadly enabling, pressure-based
instruments, consumables, and platform technology solutions
to the
worldwide
biotechnology,
biotherapeutics, cosmeceuticals,
nutraceuticals, and
food
&
beverage
industries,
today announced
that
its
pending merger partner Cannaworx, Inc.
will
be launching its
patented and proprietary immune booster supplement
by
mid-July
2020. The
Company believes that
post-launch, this
product
could be
one of the
very
few, and perhaps the
only, OTC
(over the
counter), FDA registered,
hemp-containing supplements with an immune
booster claim.
The
immune system is responsible for
protecting the body against illness
and disease. It is comprised of a
complex set of components, including organs (e.g., spleen), the
lymph system, antibodies, bone marrow, and white blood cells (e.g.,
T cells,
which
play an important role in the immune
response).
Since the
immune system's job is to keep us
healthy by defending
against invaders (e.g.,
bacteria and viruses), it is important to keep our immune
system as
strong
as
possible. Healthy living
is the primary
recommended strategy to achieve
this goal – but
this
strategy can be powerfully
supplemented with high
quality immune
boosters. Immune
boosters have become very
popular in
recent
years;
for example, it is estimated that
the global
immune booster market
will
exceed $25B by 2025.
The
active ingredient in the
Cannaworx
immune
booster is a patented,
proprietary blend of 44 amino acid fragments
from
pepsin. The product
has the
unique and beneficial ability of
significantly
increasing
the
number of T helper cells in the human body. T helper cells serve a
critical function in the human
immune
response as they enable macrophage cells to kill and consume
bacteria, viruses,
and other invaders. Consequently,
the
company's product
is
different
from most other immune boosters
on
the
market
today,
as it is a novel and potent T cell stimulator, enabling the immune
system to aggressively defend against invasions of disease-causing
bacteria, viruses,
and other pathogens.
Dr. Bobby
Ghalili, co-founder and President of Cannaworx, commented:
"To further enhance
the immune boosting effect, we added hemp seed oil (no THC)
to our
patented
formulation. Hemp seed oil is rich in essential fatty acids (e.g.,
omega-6 and omega-3) and antioxidants that may help fight
inflammation, cancer, diabetes, and heart disease. Omega-3 is also
thought to have a positive impact on the bowel microbiome as a
prebiotic,
providing
further support to the immune system.
The manufacturing process of the patented 44 amino acid
fragment
formulation
is highly
proprietary, protected,
and would
be nearly
impossible to
imitate."
Dr.
Ghalili continued: "At the frontline of
our commercialization strategy is our novel active ingredient,
our addition of
hemp seed
oil, and our
FDA
registration with an issued NDI number (1140).
We plan
to introduce
our
unique immune booster initially to
the U.S.
market
through
the network of over 50 sales representatives
who are part of the Five Leaf Labs pending acquisition
announced on May 19, 2020. We are also
working
closely with in-coming CEO Jim Morrison to expand
on-line
and retail
channels.
With this novel patented product, its unique immune boosting
capabilities, its enhanced hemp
seed oil addition, and a strong sales
and distribution network, we expect the
upcoming
launch of our immune
booster to
generate
strong revenue immediately
following its mid-July
product
launch."
As
recently announced, Cannaworx Inc., SkinScience Labs, and Pressure
BioSciences, Inc. have agreed to merge into a new company
that
will be named Availa Bio. Availa
Bio will
have an opening IP portfolio of 31 issued and many more
pending patents, an existing
worldwide base of hundreds of corporate and thousands of retail
customers, and existing revenue from multiple products already on
the market. Availa Bio
will
be
led by Mr. Jim Morrison, the
former
President of L'Oréal,
Sexy Hair, StarShop, and Graham Webb. Mr. Morrison is universally
regarded as one of the top brand strategists in the personal care
space worldwide.
The
Letter of Intent between Cannaworx and SkinScience Labs, and the
Letter of Intent between PBI and Cannaworx, Inc. are subject to
certain closing conditions, including completion of all due
diligence and acquisition financing.
About Pressure BioSciences, Inc.
Pressure
BioSciences,
Inc.
(OTCQB:
PBIO)
is
a
leader
in
the
development
and
sale
of
innovative,
broadly
enabling,
pressure-based
solutions
for
the
worldwide
life
sciences
and
other
industries.
Our
products
are
based
on
the
unique
properties
of
both
constant
(i.e.,
static)
and
alternating
(i.e.,
pressure
cycling
technology,
or
PCT)
hydrostatic
pressure.
PCT
is a
patented
enabling
technology
platform
that
uses
alternating
cycles
of hydrostatic
pressure
between
ambient
and
ultra-high
levels
to safely
and
reproducibly
control
bio-molecular
interactions
(e.g.,
cell
lysis,
biomolecule
extraction).
Our
primary
focus
is
in
the
development
of PCT-based
products
for
biomarker
and
target
discovery,
drug
design
and
development,
biotherapeutics
characterization
and
quality
control,
soil
&
plant
biology,
forensics,
and
counter-bioterror
applications.
Additionally,
major
new
market
opportunities
have
emerged
in
the
use
of
our
pressure-based
technologies
in
the
following
areas:
(1)
the
use
of our
recently
acquired,
patented
technology
from
BaroFold,
Inc.
(the
"BaroFold"
technology)
to
allow
entry
into
the
bio-pharma
contract
services
sector,
and
(2)
the
use
of our
recently-patented,
scalable,
high-efficiency,
pressure-based
Ultra
Shear
Technology
("UST")
platform
to
(i)
create
stable
nanoemulsions
of otherwise
immiscible
fluids
(e.g.,
oils
and
water)
and
to
(ii)
prepare
higher
quality,
homogenized,
extended
shelf-life
or room
temperature
stable
low-acid
liquid
foods
that
cannot
be
effectively
preserved
using
existing
non-thermal
technologies.
Forward Looking Statements
This
press
release
contains
forward-looking
statements.
These
statements
relate
to future
events
or
our
future
financial
performance
and
involve
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
or
our
industry's
actual
results,
levels
of
activity,
performance
or
achievements
to
be
materially
different
from
any
future
results,
levels
of activity,
performance
or
achievements
expressed,
implied
or inferred
by these
forward-looking
statements.
In some
cases,
you can
identify
forward-looking
statements
by
terminology
such
as
"may,"
"will,"
"should,"
"could,"
"would,"
"expects,"
"plans,"
"intends,"
"anticipates,"
"believes,"
estimates,"
"predicts,"
"projects,"
"potential"
or "continue"
or the
negative
of
such
terms
and
other
comparable
terminology.
These
statements
are
only
predictions
based
on
our
current
expectations
and projections
about
future
events.
You
should
not
place
undue
reliance
on
these
statements.
In evaluating
these
statements,
you
should
specifically
consider
various
factors.
Actual
events
or results
may
differ
materially.
These
and
other
factors
may cause
our actual
results
to
differ
materially
from
any
forward-looking
statement.
These
risks,
uncertainties,
and
other
factors
include,
but
are
not
limited
to,
the
risks
and
uncertainties
discussed
under
the
heading
"Risk
Factors"
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2019,
and
other
reports
filed
by
the
Company
from
time
to
time
with
the
SEC.
The
Company
undertakes
no
obligation
to
update
any
of the
information
included
in this
release,
except
as
otherwise
required
by law.
For more information about PBI and this press release, please click
on the following website link: http://www.pressurebiosciences.com Please
visit us on Facebook, LinkedIn, and Twitter.
Press Contacts:
Richard T. Schumacher,
President & CEO
(508) 230-1828 (T)
Jeffrey N. Peterson,
Chairman
(650) 703-8557 (T)
Source: Pressure BioSciences, Inc.
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024